product summary
Loading...
company name :
R&D Systems
product type :
other
product name :
Human AICL/CLEC-2B (NP_005118) VersaClone cDNA
catalog :
RDC1627
quantity :
10 ug
price :
257 USD
more info or order :
product information
master code :
RDC1627
SKU :
RDC1627
product name :
Human AICL/CLEC-2B (NP_005118) VersaClone cDNA
unit size :
10 ug
description :
R&D Systems Human AICL/CLEC-2B (NP_005118) VersaClone cDNA clone contains the complete ORF for AICL/CLEC-2B, along with a Kozak consensus sequence for optimal translation initiation. The gene insert is flanked with convenient multiple cloning sites which can be used to easily cut and transfer the gene cassette into your desired expression vector. The AICL/CLEC-2B insert is sequence verified and the entire plasmid DNA and insert translated sequences are provided.
target :
AICL/CLEC-2B
category :
cDNA Clones
species :
Human
gene symbol :
CLEC2B
accessionNumbers :
NP_005118
USD :
257 USD
alt names :
Activation-induced C-type lectin, AICLC-type lectin superfamily member 2, CLEC2B, CLEC-2B, CLECSF2, CLECSF2IFN-alpha-2b-inducing-related protein 1, C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamilymember 2 (activation-induced), C-type lectin domain family 2 member B, C-type lectin domain family 2, member B, HP10085, IFN-alpha2b-inducing related protein 1, IFNRG1
storage :
Store the unopened product at -20 to -70 ░C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
browse more products
questions and comments